---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-019046"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2022-12-30T23:59:59+00:00"
generated_at: "2026-06-20T21:23:00.081312+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aytu settles derivative lawsuits over 2021 option grants; cancels 25% of awards, adds independent directors

## Summary
- Settlement cancels 387,804 of 1,551,216 shares (25%) from 2021 option grants to directors and officers.
- Company to add two independent directors within six months; one appointed as Compensation Committee chair.
- Non-employee director compensation capped at $175,000 annually through 2024; new equity plan with reserve ≤15% of outstanding.
- No further equity awards to defendants under 2015 plan; lead independent director to be designated.
- Aytu to pay up to $425,000 in attorneys' fees; no admission of wrongdoing.

## SEC filing metadata
- accession: 0001558370-22-019046
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2022-12-30T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01, 99.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837022019046/0001558370-22-019046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837022019046/aytu-20221228x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-019046
- JSON: https://secwatch.observer/filing/0001558370-22-019046.json
- Plain text: https://secwatch.observer/filing/0001558370-22-019046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.